Valuation: GENFIT

Market Cap 60Cr 69Cr 57Cr 52Cr 97Cr 6.65TCr 97Cr 677.34Cr 261.73Cr 3.37TCr 260.21Cr 254.43Cr 11TCr P/E 2026 *
30.9x
P/E 2027 * 68.5x
Enterprise Value 55Cr 63Cr 52Cr 47Cr 88Cr 6.08TCr 89Cr 619.67Cr 239.45Cr 3.08TCr 238.06Cr 232.77Cr 9.83TCr EV / Sales 2026 *
5.48x
EV / Sales 2027 * 4.19x
Free-Float
86.89%
Yield 2026 *
-
Yield 2027 * -
1 day+2.04%
1 week-2.44%
Current month-15.13%
1 month-7.83%
3 months+26.58%
6 months+39.86%
Current year+127.92%
1 week 11.66
Extreme 11.66
14.5
1 month 11.66
Extreme 11.66
14.98
Current year 5.05
Extreme 5.05
15.48
1 year 3.05
Extreme 3.048
15.48
3 years 2.62
Extreme 2.62
15.48
5 years 2.62
Extreme 2.62
15.48
10 years 2.62
Extreme 2.62
35.65
Manager TitleAgeSince
Chief Executive Officer 58 16/09/2019
Director of Finance/CFO 52 22/04/2021
Chief Tech/Sci/R&D Officer - 27/11/2025
Director TitleAgeSince
Chairman 70 16/06/2017
Director/Board Member 54 15/09/1999
Director/Board Member 58 16/06/2017
Date Insider Type Main position Quantity % Market Cap. Importance
05/03/26 Exercice

Chief Operating Officer

11,250 0.0225%
05/03/26 Exercice

Chief Operating Officer

7,083 0.0142%
05/03/26 Sell

Chief Operating Officer

7,083 0.0142%
Change 5-day change 1-year change 3-year change Capi.($)
+2.04%-2.44% - - 68Cr
Average +2.04%
Weighted average by Cap. +2.04%

Financials

2026 *2027 *
Net sales 10Cr 12Cr 9.48Cr 8.61Cr 16Cr 1.11TCr 16Cr 113.16Cr 44Cr 563.09Cr 43Cr 43Cr 1.79TCr 13Cr 15Cr 12Cr 11Cr 20Cr 1.41TCr 21Cr 143.32Cr 55Cr 713.16Cr 55Cr 54Cr 2.27TCr
Net income 2.29Cr 2.64Cr 2.16Cr 1.96Cr 3.68Cr 253.26Cr 3.7Cr 26Cr 9.97Cr 128.45Cr 9.92Cr 9.7Cr 409.44Cr 90.67L 1.05Cr 85.69L 77.8L 1.46Cr 100.37Cr 1.47Cr 10Cr 3.95Cr 51Cr 3.93Cr 3.84Cr 162.26Cr
Net Debt -5.11Cr -5.9Cr -4.83Cr -4.39Cr -8.22Cr -565.75Cr -8.27Cr -58Cr -22Cr -286.95Cr -22Cr -22Cr -914.65Cr -6.76Cr -7.8Cr -6.39Cr -5.8Cr -11Cr -747.87Cr -11Cr -76Cr -29Cr -379.32Cr -29Cr -29Cr -1.21TCr
Logo GENFIT
GENFIT is a biopharmaceutical company in late-stage development focused on the discovery and development of innovative therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, in particular due to a lack of approved treatments. GENFIT is a leading innovator in the field of nuclear receptor-based drug discovery with a rich history and a solid scientific heritage spanning nearly two decades. The company has offices in Lille, Paris, Zurich and Cambridge, MA (USA).
Employees
161
Date Price Change Volume
16/26/16 €12.00 +2.04% 2,46,907
15/26/15 €11.76 -5.77% 3,67,572
14/26/14 €12.48 -4.15% 2,81,734
11/26/11 €13.02 -4.96% 4,24,279
10/26/10 €13.70 +11.38% 4,75,388
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
12.00EUR
Average target price
18.10EUR
Spread / Average Target
+50.83%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GNFT Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!